← Human Trials & Peer-Reviewed Studies
A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis
Plain-language guide to PMID 17178185 (2008): placebo-controlled randomized controlled trial study of Triptorelin in 30 patients, endometriosis.
Key Facts
- PMID
- 17178185
- Journal
- European journal of obstetrics, gynecology, and reproductive biology
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Loverro G et al. (6 authors)
- DOI
- 10.1016/j.ejogrb.2006.10.034
What This Study Did, in Plain Language
What Was Tested
Researchers studied Triptorelin in the context of endometriosis in this randomized controlled trial publication.
To investigate the role of adjuvant treatment with gonadotropin-releasing-hormone agonist (GnRHa) following conservative surgical treatment of endometriosis.
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial to compare the effects of 3-month treatment with triptorelin depot-3.75 i.m.
Who Took Part
The abstract describes 30 patients taking part.
PubMed indexes the participants as adults, women only.
(30 patients) versus expectant management using placebo injection (30 patients).
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Triptorelin group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Chemotherapy, Adjuvant, Endometriosis, Fertility, Laparoscopy, Luteolytic Agents, Pelvic Pain and Pregnancy Rate.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Triptorelin in 30 patients in people with endometriosis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.
More context: the Triptorelin compound page, Endometriosis research.
Our Notes on the Compound
Triptorelin: A 10-amino-acid GnRH analog (Trelstar, Decapeptyl, Triptodur) used in prostate cancer, early puberty and fertility protocols.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.